

## Ghana Support for Pneumococcal Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Ghana					
<b>2. Grant number:</b> 1819-GHA-12d-X /12-GHA-08a-Y					
<b>3. Date of Decision Letter:</b> 19 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 11 July 2014					
<b>5. Programme title:</b> New Vaccine Support (NVS), Pneumococcal Routine					
<b>6. Vaccine type:</b> Pneumococcal					
<b>7. Requested product presentation and formulation of vaccine:</b> Pneumococcal (PCV13), 4 dose(s) per vial , LIQUID					
<b>8. Programme duration<sup>1</sup>:</b> 2012 -2019					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2012-2018	2019	Total <sup>2</sup>		
Programme Budget (US\$)	US\$83,660,980 <sup>3</sup>	US\$5,920,000	US\$89,580,980		
<b>10. Vaccine introduction grant (in US\$):</b>					
		<table border="1" style="margin: auto; border-collapse: collapse;"> <tr> <td style="text-align: center;"><b>16 December 2011</b></td> </tr> <tr> <td style="text-align: center;">US\$305,000</td> </tr> </table>		<b>16 December 2011</b>	US\$305,000
<b>16 December 2011</b>					
US\$305,000					
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
Type of supplies to be purchased with Gavi funds in each year	2017-2018	2019			
Number of Pneumococcal vaccines doses		1,693,400			
Annual Amounts (US\$)	US\$83,660,980 <sup>5</sup>	US\$5,920,000			
<b>12. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>3</sup> This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<sup>4</sup> This is the amount that Gavi has approved.

<sup>5</sup> This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<b>13. Self-procurement:</b> Not applicable	
<b>14. Co-financing obligations:</b> Reference code: 1819-GHA-12d-X-C According to the co-financing policy, the Country falls within the group Preparatory transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2019
Number of vaccine doses	770,400
Number of AD syringes	789,200
Number of re-constitution syringes	
Number of safety boxes	8,700
Value of vaccine doses (US\$)	US\$2,272,395
Total co-financing payments (US\$) (including freight)	US\$2,336,500
<b>15. Operational support for campaigns:</b> Not applicable	
<b>16. Additional reporting requirements:</b>	
Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
<b>17. Financial clarifications:</b> Not applicable	
<b>18. Other conditions:</b> Not applicable	

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
19 March 2019